You guys think is it possible?
Analysis of MBOT’s Revenue Potential in 2026
Based on current public data and market analysis, reaching an annual revenue goal of $5 million to $10 million in 2026 is challenging but achievable.
- Revenue Inflection Point: The Launch of the Liberty System
• Full Market Release: The company announced the official full-scale launch of its flagship product, the Liberty Robotic Surgical System, in the United States on April 13, 2026. This marks the transition from R&D to the commercial revenue stage.
• Analyst Forecasts: Average analyst estimates for 2026 annual revenue sit at approximately $4 million. While slightly below the $5 million threshold, quarterly projections suggest Q4 2026 could reach $300k to $1M in a single month. If sales momentum remains strong at year-end, hitting $5 million is within reach.
- Required Sales Volume (Assuming $2,000 per Unit)
To hit your targets at a $2,000 price point (covering disposables or amortized system use), the numbers break down as follows:
• $5 Million Goal: Requires 2,500 units/procedures.
• $10 Million Goal: Requires 5,000 units/procedures.
Hospital Penetration Scenarios:
• High Usage (2 procedures/week): Needs ~50 hospitals to reach $10 million.
• Moderate Usage (1 procedure/week): Needs ~50 hospitals to reach $5 million; ~100 hospitals for $10 million.
- Potential Customer Base in the U.S.
There are approximately 6,100 hospitals in the U.S., but the target market is more specific:
• Core Target (Interventional Radiology): Roughly 3,300 to 3,500 hospitals have the necessary catheter labs or interventional departments.
• Market Penetration:
• To reach $5M, MBOT needs to penetrate only 1.5% of the core target hospitals.
• To reach $10M, it needs to penetrate roughly 3%.
- Key Drivers and Risks
• Sales Expansion: MBOT is expanding from 8 to 12 sales territories by the end of 2026. Each territory needs to secure roughly 4 to 8 hospitals to meet the base goal.
• Disposable Model: The Liberty system uses a single-use disposable design, which creates recurring revenue as procedure volumes grow.
• Execution Risk: As of late 2025, MBOT had near-zero revenue. Jumping to $5M+ in a single year requires flawless execution in a market where hospital procurement cycles can be slow.
Conclusion:
Achieving $5 million is a realistic "growth curve" target for a company with FDA clearance and 12 sales territories. Reaching $10 million would likely require a significant contribution from international markets (EMEA) or an aggressive adoption rate in Outpatient Surgery Centers (ASCs) beyond traditional hospitals.